Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study

Table 2

Glycemic variability at baseline and after three months.

	Ranolazine			No ranolazine
	Baseline	3 months	value	Baseline	3 months	value
FPG (mg/dl)			0.072			0.460
Hb1Ac (%)			<0.001			0.928
TIR (%)	61 (46, 74)	78 (73, 96)	0.001	51 (28, 71)	62(15, 77)	0.408
TBR (%)	0 (0, 13)	0 (0, 0)	0.116	0 (0, 9)	0.5 (0.5, 10)	0.929
TAR (%)	28 (10, 42)	16 (4, 26)	0.010	40 (24, 67)	33 (10, 85)	0.277
SD (mg/dl)			0.023			0.269
CV (%)			0.020			0.186
MAGE (mg/dl)			0.042			0.653

compared with 3-month results in the ranolazine cohort; values are or median(Q1, Q3). CV: coefficient of variation; FPG: fasting plasma glucose; HbA1c: haemoglobin A1c; MAGE: mean amplitude glycemic excursions; SD: standard deviation; TAR: time above range; TBR: time below range; TIR: time in range.